Karolinska Institutet and Gustavsberg primary care center
Stockholm, Stockholm County, 13440, Sweden
NCT Number: NCT01636791
Background: Common mental illness, such as anxiety disorders and depression, is the main cause for sick leave in Sweden. Cognitive behavior therapy (CBT) has been shown to be effective in alleviating target symptoms of these disorders, but its effect on sick leave rates has not been sufficiently addressed. The investigators have developed an intervention called return to work (RTW), which is based in cognitive behavioral theory, that has a primary aim of helping sick-listed patients with common mental illness return to work. This new treatment has not been evaluated in a randomized controlled trial.
Aims: The aim of this study is to investigate the effect of CBT and RTW for common mental illness in a randomized controlled trial conducted in primary care. Participants will be randomized to diagnosis specific CBT (n=70), RTW (n=70), or a combination of the two treatments (n=70). Main outcomes are days of sick leave and clinician severity rating of psychiatric symptoms. This study could contribute to new knowledge regarding how to best treat patients on sick leave with common mental illness.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Stockholm, Stockholm County, 13440, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
Time frame: 1 year
Number of days on sick leave
Time frame: Baseine, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in CSR at post-treatment, 26 week follow-up, and 52 week follow-up compared to baseline.
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in MADRS-S at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in WAI at post-treatment, 26 week follow-up, 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder, 26 week follow-up, 52 week follow-up
Change in ISI at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in HAI at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in PSS at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in TIC-P at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in QOLI at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 feel follow-up, 52 week follow-up
Change in EQ5D at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in SDS at post-treatment, 26 week follow-up, and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in SRH-5 at post-treatment, 26 week follow-up and 52 week follow-up
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in OCI-R at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in LSAS-SR at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in PDSS-SR at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in PSWQ at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.
Time frame: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up
Change in PTSDSS at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.
Time frame: Baseline, post-treatment (variable depending on disorder)
Change in inflammatory cytokines at post-treatment
Karolinska Institutet
Other
Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Common Mental Illness in Primary Care: a Randomized Clinical Trial
Acronym: CBT vs RTW I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01667822
Anxiety Disorders, Depressive Disorder
Stockholm, Stockholm County, Sweden
View Trial DetailsNCT01667809
Anxiety Disorders, Depressive Disorder
Stockholm, Stockholm County, Sweden
View Trial DetailsNCT03542396
ADHD, Anxiety Disorders
Tübingen, Baden-Wurttemberg, Germany
View Trial DetailsNCT02085512
Anxiety Disorders, Depressive Disorder
Jerusalem, Israel
View Trial Details